Test Catalog

Test Id : TOPSU

Not Orderable

Targeted Opioid Screen, Random, Urine

Download
Overview

Test Catalog

Useful For
Suggests clinical disorders or settings where the test may be helpful

Qualitatively (present vs not detected) identifying 33 opioid compounds (parent drug and metabolites) in urine to help determine compliance or identify illicit opioid drug use

 

This test is not intended for use in employment-related testing.

Method Name
A short description of the method used to perform the test

Only orderable as part of profile. For more information see:

-CSMPU / Controlled Substance Monitoring Panel, Random, Urine

-TOSU / Targeted Opioid Screen, Random, Urine

 

Liquid Chromatography-Tandem Mass Spectrometry, High-Resolution Accurate Mass (LC-MS/MS HRAM)

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Targeted Opioid Screen, U

Aliases
Lists additional common names for a test, as an aid in searching

Codeine (Tylenol #3)

Codeine-6-beta-glucuronide (codeine metabolite)

Morphine (Avinza, Kadian, MS Contin)

Morphine-6-beta-glucuronide (morphine metabolite

6-monoacetylmorphine (heroin metabolite)

Norhydrocodone (hydrocodone metabolite)

Dihydrocodeine(hydrocodone metabolite)

Hydromorphone-3-beta-glucuronide (hydromorphone metabolite)

Noroxycodone (oxycodone metabolite)

Oxymorphone (Numorphan, Opana)

Oxymorphone-3-beta-glucuronide (Oxymorphone metabolite)

Noroxymorphone (Oxymorphone metabolite)

Fentanyl (Actiq, Duragesic, Fentora)

Norfentanyl (fentanyl metabolite)

Meperidine (Demerol)

Normeperidine (Meperidine metabolite)

Naloxone (Narcan)

Naloxone-3-beta-glucuronide (Naloxone metabolite)

EDDP (Methadone metabolite)

Propoxyphene (Darvon, Darvocet)

Norpropoxyphene (propoxyphene metabolite)

Tramadol (Tradol, Ultram, Ultracet)

O-desmethyltramadol (Tramadol metabolite)

Tapentadol (Nucynta)

N-desmethyltapentadol (Tapentadol metabolite)

Tapentadol-beta-glucuronide (Tapentadol metabolite)

Buprenorphine (Buprenex, Suboxone)

Norbuprenorphine (Buprenorphine metabolite)

Norbuprenorphine glucuronide (Buprenorphine metabolite)

Heroin

Hydrocodone (Lortab, Norco, Vicodin)

Hydromorphone (Dilaudid, Exalgo)

Methadone (Dolophine)

Methadone metabolite (EDDP)

Opiates

Oxycodone (Endocet, Percocet, Oxycontin)

Specimen Type
Describes the specimen type validated for testing

Urine

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Only orderable as part of profile. For more information see:

-CSMPU / Controlled Substance Monitoring Panel, Random, Urine

-TOSU / Targeted Opioid Screen, Random, Urine

 

Supplies: Sarstedt 5 mL Aliquot Tube (T914)

Collection Container/Tube: Plastic urine container

Submission Container/Tube: Plastic, 5-mL tube

Specimen Volume: 1 mL

Collection Instructions:

1. Collect a random urine specimen.

2. No preservative

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory

0.5 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Gross hemolysis Reject
Gross icterus Reject

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Urine Refrigerated (preferred) 14 days
Frozen 28 days
Ambient 72 hours

Useful For
Suggests clinical disorders or settings where the test may be helpful

Qualitatively (present vs not detected) identifying 33 opioid compounds (parent drug and metabolites) in urine to help determine compliance or identify illicit opioid drug use

 

This test is not intended for use in employment-related testing.

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Opioids are a large class of medications commonly used to relieve acute and chronic pain or help manage opioid abuse and dependence. Medications that fall into this class include buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, tapentadol, tramadol, and others. Opioids work by binding to the opioid receptors that are found in the brain, spinal cord, gastrointestinal tract, and other organs.

 

Common side effects include drowsiness, confusion, nausea, constipation, and, in severe cases, respiratory depression depending on the dose. These medications can also produce physical and psychological dependence and have a high risk for abuse and diversion, which is one of the main reasons many professional practice guidelines recommend compliance testing in patients prescribed these medications.

 

Opioids are readily absorbed from the gastrointestinal tract, nasal mucosa, lungs, and after subcutaneous or intermuscular injection. Opioids are primarily excreted from the kidney in both free and conjugated forms. This assay doesn't hydrolyze the urine sample and looks for both parent drugs and metabolites (including glucuronide forms). The detection window for most opioids in urine is approximately 1 to 3 days with longer detection times for some compounds (ie, methadone).

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Only orderable as part of profile. For more information see:

-CSMPU / Controlled Substance Monitoring Panel, Random, Urine

-TOSU / Targeted Opioid Screen, Random, Urine

 

Not Detected

 

Cutoff concentrations:

Codeine: 25 ng/mL

Codeine-6-beta-glucuronide: 100 ng/mL

Morphine: 25 ng/mL

Morphine-6-beta-glucuronide: 100 ng/mL

6-Monoacetylmorphine: 25 ng/mL

Hydrocodone: 25 ng/mL

Norhydrocodone: 25 ng/mL

Dihydrocodeine: 25 ng/mL

Hydromorphone: 25 ng/mL

Hydromorphone-3-beta-glucuronide: 100 ng/mL

Oxycodone: 25 ng/mL

Noroxycodone: 25 ng/mL

Oxymorphone: 25 ng/mL

Oxymorphone-3-beta-glucuronide: 100 ng/mL

Noroxymorphone: 25 ng/mL

Fentanyl: 2 ng/mL

Norfentanyl: 2 ng/mL

Meperidine: 25 ng/mL

Normeperidine: 25 ng/mL

Naloxone: 25 ng/mL

Naloxone-3-beta-glucuronide: 100 ng/mL

Methadone: 25 ng/mL

2-Ethylidene-1,5-dimethyl-3,3-diphenypyrrolidine: 25 ng/mL

Propoxyphene: 25 ng/mL

Norpropoxyphene: 25 ng/mL

Tramadol: 25 ng/mL

O-desmethyltramadol: 25 ng/mL

Tapentadol: 25 ng/mL

N-desmethyltapentadol: 50 ng/mL

Tapentadol-beta-glucuronide: 100 ng/mL

Buprenorphine: 5 ng/mL

Norbuprenorphine: 5 ng/mL

Norbuprenorphine glucuronide: 20 ng/mL

Interpretation
Provides information to assist in interpretation of the test results

If an opioid or its corresponding metabolites is identified (present), it indicates that the patient has used the respective opioid in the recent past. The absence of expected opioids or their metabolites may indicate noncompliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted or adulterated urine, or limitations of testing. The concentration of the drug must be greater than or equal to the cutoff to be reported as present. If a specific drug concentration is required, the laboratory must be contacted within 2 weeks of specimen collection/testing to request quantification by a second analytical technique at an additional charge.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

No significant cautionary statements

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Gutstein HB, Akil H: Opioid analgesics. In: Brunton LL, Lazo JS, Parker KL. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill; 2006:chap 21

2. Chronic Pain in America: Roadblocks to Relief, survey conducted for the American Pain Society, The American Academy of the Pain Medicine and Janssen. Pharmaceutica; 1999

3. Magnani B, Kwong T: Urine drug testing for pain management. Clin Lab Med. 2012;32(32):379-390. doi: 10.1016/j.cll.2012.07.001

Method Description
Describes how the test is performed and provides a method-specific reference

The urine sample is diluted with internal standard and then analyzed by liquid chromatography- tandem mass spectrometry using a high resolution-accurate mass orbi-trap detector.(Unpublished Mayo method)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Saturday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

2 to 4 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

14 days

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

80364 (G0481 if appropriate)

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
TOPSU Targeted Opioid Screen, U 95796-9
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
42323 Codeine 19411-8
42324 Codeine-6-beta-glucuronide 89310-7
42325 Morphine 19597-4
42326 Morphine-6-beta-glucuronide 89308-1
42327 6-monoacetylmorphine 19321-9
42328 Hydrocodone 19482-9
42329 Norhydrocodone 89304-0
42330 Dihydrocodeine 19446-4
42331 Hydromorphone 19486-0
42332 Hydromorphone-3-beta-glucuronide 89309-9
42333 Oxycodone 19642-8
42334 Noroxycodone 89303-2
42335 Oxymorphone 19646-9
42336 Oxymorphone-3-beta-glucuronide 89301-6
42337 Noroxymorphone 89302-4
42338 Fentanyl 59673-4
42339 Norfentanyl 43199-9
42340 Meperidine 19532-1
42341 Normeperidine 27920-8
42342 Naloxone 42618-9
42343 Naloxone-3-beta-glucuronide 89307-3
42344 Methadone 19550-3
42345 EDDP 93495-0
42346 Propoxyphene 19429-0
42347 Norpropoxyphene 19632-9
42348 Tramadol 19710-3
42349 O-desmethyltramadol 86453-8
42350 Tapentadol 72485-6
42351 N-desmethyltapentadol 89306-5
42352 Tapentadol-beta-glucuronide 89300-8
42353 Buprenorphine 93494-3
42354 Norbuprenorphine 82371-6
42355 Norbuprenorphine glucuronide 89305-7
65059 Opioid Interpretation 69050-3

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports